Total Payments
$175,958
2024 Payments
$36,530
Companies
6
Transactions
60
Payment Breakdown by Category
Consulting$117,588 (66.8%)
Other$38,800 (22.1%)
Travel$18,824 (10.7%)
Food & Beverage$746.29 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $117,588 | 35 | 66.8% |
| Honoraria | $38,800 | 12 | 22.1% |
| Travel and Lodging | $18,824 | 4 | 10.7% |
| Food and Beverage | $746.29 | 9 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Agios Pharmaceuticals, Inc. | $139,658 | 50 | $0 (2024) |
| SWEDISH ORPHAN BIOVITRUM AB | $22,555 | 3 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $5,440 | 1 | $0 (2020) |
| GENZYME CORPORATION | $3,740 | 1 | $0 (2024) |
| Dova Pharmaceuticals | $3,110 | 3 | $0 (2020) |
| SOBI, INC | $1,455 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $36,530 | 11 | SWEDISH ORPHAN BIOVITRUM AB ($22,555) |
| 2023 | $7,643 | 8 | Agios Pharmaceuticals, Inc. ($7,643) |
| 2022 | $10,978 | 13 | Agios Pharmaceuticals, Inc. ($10,978) |
| 2021 | $8,880 | 2 | Agios Pharmaceuticals, Inc. ($8,880) |
| 2020 | $62,333 | 9 | Agios Pharmaceuticals, Inc. ($53,893) |
| 2019 | $39,714 | 11 | Agios Pharmaceuticals, Inc. ($39,604) |
| 2018 | $9,881 | 6 | Agios Pharmaceuticals, Inc. ($9,881) |
All Payment Transactions
60 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/17/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $2,775.00 | General |
| Category: Genetically Defined Disease | ||||||
| 07/03/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $3,740.00 | General |
| 06/12/2024 | SWEDISH ORPHAN BIOVITRUM AB | — | Travel and Lodging | Cash or cash equivalent | $16,505.33 | General |
| 06/12/2024 | SWEDISH ORPHAN BIOVITRUM AB | — | Consulting Fee | Cash or cash equivalent | $4,180.00 | General |
| 05/29/2024 | SOBI, INC | DOPTELET (Drug) | Consulting Fee | Cash or cash equivalent | $1,320.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 05/18/2024 | SWEDISH ORPHAN BIOVITRUM AB | — | Consulting Fee | Cash or cash equivalent | $1,870.00 | General |
| 05/01/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| Category: Genetically Defined Disease | ||||||
| 04/17/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Travel and Lodging | Cash or cash equivalent | $1,564.66 | General |
| Category: Genetically Defined Disease | ||||||
| 04/04/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $135.18 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 02/20/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Honoraria | Cash or cash equivalent | $1,110.00 | General |
| Category: Genetically Defined Disease | ||||||
| 02/15/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: Genetically Defined Disease | ||||||
| 12/07/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $68.56 | General |
| Category: Genetically Defined Disease | ||||||
| 10/06/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| Category: Genetically Defined Disease | ||||||
| 07/21/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $1,387.50 | General |
| Category: Genetically Defined Disease | ||||||
| 05/26/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: Genetically Defined Disease | ||||||
| 03/13/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: Genetically Defined Disease | ||||||
| 03/13/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| Category: Genetically Defined Disease | ||||||
| 01/05/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Honoraria | Cash or cash equivalent | $1,110.00 | General |
| Category: Genetically Defined Disease | ||||||
| 01/05/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $81.94 | General |
| Category: Genetically Defined Disease | ||||||
| 12/13/2022 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Honoraria | Cash or cash equivalent | $1,110.00 | General |
| Category: Genetically Defined Disease | ||||||
| 12/11/2022 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $81.94 | General |
| Category: Genetically Defined Disease | ||||||
| 12/02/2022 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $971.25 | General |
| Category: Genetically Defined Disease | ||||||
| 11/18/2022 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $638.25 | General |
| Category: Genetically Defined Disease | ||||||
| 11/09/2022 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| Category: Genetically Defined Disease | ||||||
| 10/26/2022 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Honoraria | Cash or cash equivalent | $1,100.00 | General |
| Category: Genetically Defined Disease | ||||||
About Dr. Rachael Grace, MD
Dr. Rachael Grace, MD is a Pediatrics healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144335100.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rachael Grace, MD has received a total of $175,958 in payments from pharmaceutical and medical device companies, with $36,530 received in 2024. These payments were reported across 60 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($117,588).
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatric Hematology-Oncology
- Location Boston, MA
- Active Since 08/20/2006
- Last Updated 03/18/2015
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1144335100
Products in Payments
- PYRUKYND (Drug) $27,400
- PROMACTA (Drug) $5,440
- Doptelet (Drug) $3,110
- DOPTELET (Drug) $1,455
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Boston
Dr. R Ezekowitz, Mbch Dphl, MBCH DPHL
Pediatrics — Payments: $1.2M
Pediatrics $1.2M
Stephen Pelton, Md, MD
Pediatrics — Payments: $456,322
Pediatrics $456,322
Tanya Laidlaw, M.d, M.D
Pediatrics — Payments: $307,922
Pediatrics $307,922
Dr. Harald Jueppner, Md, MD
Pediatrics — Payments: $202,618
Pediatrics $202,618
Dr. Thomas Kinane, Md, MD
Pediatrics — Payments: $175,709
Pediatrics $175,709
Courtney Hanna
Pediatrics — Payments: $149,231
Pediatrics $149,231